

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373

Provisional Stakeholder List


| Consultees | Commentators (no right to submit or appeal) |
|--|---|
| Company | General |
| Eli Lilly and Company (imlunestrant) | All Wales Therapeutics and Toxicology |
| Eli Lilly and Company (imlunestrant) Patient/carer groups Black Health Agency for Equality Breast Cancer Now Breast Cancer UK Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Inflammatory Breast Cancer (IBC) Network UK Lobular Breast Cancer UK Macmillan Cancer Support Maggie's Centres Make 2nds Count Marie Curie MET UP UK Prevent Breast Cancer South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care Healthcare professional groups Association of Breast Surgery Association of Cancer Physicians | |
| British Geriatrics Society British Institute of Radiology British Opcology Pharmacy | Alliance Healthcare (Distribution) Ltd (exemestane)Amarox (capecitabine) |
| British Oncology Pharmacy Association | AstraZeneca (fulvestrant) |
| British Psychosocial Oncology Society | Bristol Myers Squibb Pharmaceuticals |
| British Society of Interventional | (paclitaxel) |
| Radiology | Consilient Health Ltd (docetaxel, |
| Cancer Research UK | exemestane, gemcitabine, vinorelbine) |
| | , |
| Royal College of General Practitioners | |

Provisional stakeholder list for the evaluation of imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373 Issue date: April 2024



Consultees Commentators (no right to submit or appeal) Royal College of Nursing Dr. Reddy's Laboratories (capecitabine, everolimus, fulvestrant) Royal College of Pathologists Eli Lilly (abemaciclib) Royal College of Physicians Fresenius Kabi Ltd (gemcitabine, Royal College of Radiologists paclitaxel) Royal Pharmaceutical Society Royal Society of Medicine Glenmark Pharmaceuticals (capecitabine, exemestane) Society and College of Radiographers Kent Pharma UK (exemestane, **UK Breast Cancer Group** fulvestrant) **UK Clinical Pharmacy Association** Martindale Pharmaceuticals Ltd UK Oncology Nursing Society (everolimus) Medac GmbH (vinorelbine) Others Medihealth (Northern) Ltd (exemestane) Department of Health and Social Care Menarini Stemline (elacestrant) [subject NHS England to a NICE appraisal] Morningside Healthcare Ltd (capecitabine, exemestane) Novartis (alpelisib, everolimus, ribociclib) Pfizer (docetaxel, exemestane, gemcitabine, palbociclib, paclitaxel, talazoparib [subject to a NICE evaluation]) Phoenix Healthcare Distribution Ltd (exemestane) Pierre Fabre (vinorelbine) Rivopharm (exemestane) Sandoz (everolimus, fulvestrant) Seacross Pharmaceuticals (docetaxel, paclitaxel) Sigma Pharmaceuticals (exemestane) Sun Pharmaceutical Industries Europe B.V. (fulvestrant, gemcitabine) Synchrony Pharma (gemcitabine) Teva UK (everolimus, fulvestrant) Thornton & Ross Ltd (fulvestrant) Viatris UK Healthcare Ltd (exemestane) Waverley Pharma Europe Ltd (capecitabine) Zentiva (exemestane, fulvestrant) Relevant research groups **Against Breast Cancer Breast Cancer Hope Cochrane Breast Cancer Group**

Provisional stakeholder list for the evaluation of imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373 Issue date: April 2024



| Consultees | Commentators (no right to submit or appeal) |
|------------|---|
| | Cochrane UK Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Pro-Cancer Research Fund |
| | Associated Public Health groups Public Health Wales UK Health Security Agency |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Provisional stakeholder list for the evaluation of imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373 Issue date: April 2024